Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis.
Varona JF, Landete P, Paredes R, Vates R, Torralba M, Guisado-Vasco P, Porras L, Muñoz P, Gijon P, Ancochea J, Saiz E, Meira F, Jimeno JM, Lopez-Martin JA, Estrada V. Varona JF, et al. Front Cell Infect Microbiol. 2023 Feb 22;13:1097809. doi: 10.3389/fcimb.2023.1097809. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 36909731 Free PMC article.
Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Martín-Algarra S, Fernández-Figueras MT, López-Martín JA, Santos-Briz A, Arance A, Lozano MD, Berrocal A, Ríos-Martín JJ, Espinosa E, Rodríguez-Peralto JL; Spanish Society of Pathology; Spanish Society of Medical Oncology. Martín-Algarra S, et al. Clin Transl Oncol. 2014 Apr;16(4):362-73. doi: 10.1007/s12094-013-1090-5. Epub 2013 Oct 16. Clin Transl Oncol. 2014. PMID: 24129426
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Marabelle A, et al. Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10. Lancet Oncol. 2020. PMID: 32919526 Clinical Trial.
Porocarcinoma: clinical evolution.
Vaz Salgado MA, García CG, Lopez Martin JA, Guerra E, Benito A, Sepulveda JM, Carrato A. Vaz Salgado MA, et al. Dermatol Surg. 2010 Feb;36(2):264-7. doi: 10.1111/j.1524-4725.2009.01412.x. Dermatol Surg. 2010. PMID: 20402957 No abstract available.
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.
Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A. Martin-Broto J, et al. J Clin Oncol. 2016 Jul 1;34(19):2294-302. doi: 10.1200/JCO.2015.65.3329. Epub 2016 May 16. J Clin Oncol. 2016. PMID: 27185843 Clinical Trial.
Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer.
Puig P, Erill N, Terricabras M, Subirana I, González-García J, Asensi-Puig A, Donovan MJ, Mengual L, Agulló-Ortuño MT, Olivan M, Alcaraz A, López-Martín JA, de Torres I, Rodríguez-Peralto JL, Rodríguez-Antolín A, Morote J, González-Rumayor V. Puig P, et al. BMC Res Notes. 2019 Jan 30;12(1):68. doi: 10.1186/s13104-019-4100-z. BMC Res Notes. 2019. PMID: 30700322 Free PMC article.
84 results